SEC Company Response from Akero Therapeutics, Inc. (AKRO) (CIK 0001744659) — Jul 6, 2020
Akero Therapeutics, Inc. (AKRO) (CIK 0001744659)
Date: July 6, 2020 · CIK: 0001744659 · Accession: 0001104659-20-080873
AI Filing Summary & Sentiment
File numbers found in text: 333-239685
Letter
Re:
July 6, 2020
United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549
Attention:
Courtney Lindsay
Akero Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-239685)
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), we wish to advise that as of the time of this filing, the underwriters have not yet made any distribution of the Preliminary Prospectus of Akero Therapeutics, Inc. (the “Registrant”) dated July 6, 2020. However, the underwriters are taking steps to see that all underwriters, brokers or dealers participating in the public offering of shares of the Registrant’s common stock pursuant to the above-captioned Registration Statement, as amended (the “Registration Statement”), are promptly furnished with sufficient copies of the preliminary and final prospectus to enable them to comply with the prospectus delivery requirements of Sections 5(b)(1) and (2) of the Securities Act.
We wish to advise you that the participating underwriters have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement be accelerated to 4:01 p.m. Eastern Time, on Tuesday, July 7, 2020, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm July 6, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Courtney Lindsay Re: Akero Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-239685) Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), we wish to advise that as of the time of this filing, the underwriters have not yet made any distribution of the Preliminary Prospectus of Akero Therapeutics, Inc. (the “Registrant”) dated July 6, 2020. However, the underwriters are taking steps to see that all underwriters, brokers or dealers participating in the public offering of shares of the Registrant’s common stock pursuant to the above-captioned Registration Statement, as amended (the “Registration Statement”), are promptly furnished with sufficient copies of the preliminary and final prospectus to enable them to comply with the prospectus delivery requirements of Sections 5(b)(1) and (2) of the Securities Act. We wish to advise you that the participating underwriters have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. We hereby join in the request of the Registrant that the effectiveness of the above-captioned Registration Statement be accelerated to 4:01 p.m. Eastern Time, on Tuesday, July 7, 2020, or as soon thereafter as practicable. [Signature page follows] Very truly yours, J.P. MORGAN SECURITIES LLC MORGAN STANLEY & CO. LLC JEFFERIES LLC EVERCORE GROUP L.L.C. As representatives of the Underwriters By: J.P. Morgan Securities LLC By: /s/ David Ke Name: David Ke Title: Executive Director By: Morgan Stanley & Co. LLC By: /s/ Kalli Dircks Name: Kalli Dircks Title: Executive Director By: Jefferies LLC By: /s/ Michael Brinkman Name: Michael Brinkman Title: Managing Director By: Evercore Group L.L.C. By: /s/ Maren Winnick Name: Maren Winnick Title: Senior Managing Director